Trial Condition(s):

Prevention of venous thromboembolism after MOS

BAY59-7939,Dose proportionality II for SPAF

Bayer Identifier:

12362

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2009-012008-14

Study Completed

Trial Purpose

Please see attached Study Results Summary below

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
24
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
N/A

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

CRS Clinical-Research-Services Mannheim GmbH

Mannheim, Germany, 68167

Status
Completed
 

For details, please refer to trial results

Additional Information